The Impedimed (ASX:IPD) share price rocketed 13% today. Here's why

The Impedimed (ASX: IPD) share price shot off to a great start today as the company received FDA approval for a new product in the US.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Impedimed Limited (ASX: IPD) share price was off to a flying start this morning, up 13% at market open.

The positive price movement came as the medical technology company announced it received Food and Drug Administration (FDA) clearance for a new heart monitoring device in the United States.

At the time of writing, shares in the company are up 8.7%, trading at 12.5 cents. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.08% higher.

Let's take a closer look at today's news and what it means for the Impedimed share price.

Impedimed's new product

In a statement to the ASX, Impedimed advised it has received FDA 510(k) clearance for its SOZO device to include a heart failure index (HF-Dex) as a monitoring tool for patients living with heart failure.

The 510(k) clearance is a requirement for launching new medical products in the US.

Impedimed says the HF-Dex can measure fluid levels in people using a 30-second, non-invasive test. According to the company, the product presents the data in graphical format for a quick assessment and is most useful in conjunction with other clinical data.

In addition, the Impedimed said the product "has been demonstrated in peer-reviewed publications and abstracts accepted at internationally renowned cardiology conferences", such as the American College of Cardiology and the Heart Failure Society of America.

What did management say?

Commenting on the news, Impedimed CEO Richard Carreonsaid said:

We are very pleased with this expanded clearance for SOZO that includes our heart failure index. This is a major step forward in SOZO becoming the standard of care for the management of heart failure patients.

The use of HF- Dex will provide clinicians unparalleled insights into the extracellular fluid accumulation in heart failure patients that has not otherwise been readily available to them before.

Impedimed share price snapshot

Over the past 12 months, the Impedimed share price has increased 212%, although it's up just 4% year-to-date. Today's news regains the ground lost yesterday when the company's shares fell 11.5%.

Impedimed has a market capitalisation of $171.5 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two boats on the water with crates with the words trade war in the middle.
Share Market News

Trump's tariffs blocked by trade court: Which ASX 200 stocks could benefit the most?

These 3 ASX 200 stocks have heavy tariffs exposure.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Broker Notes

How this undervalued ASX All Ords share could rocket 80% in a year

A leading fund manager expects a big turnaround for this beaten-down ASX All Ords stock.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Champion Iron, Clarity Pharmaceuticals, St Barbara, and Woodside shares are charging higher today

These shares are having a good session today. But why are investors buying them?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why ALS, Black Cat, Boss Energy, and Soul Patts shares are falling today

These shares are falling on Thursday. Let's find out why.

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Broker Notes

Up 77% in a year, guess how much more upside Macquarie tips for Eagers Automotive shares

Macquarie released its latest analysis on Eagers Automotive fast rising shares this morning.

Read more »

Boy looks quizzical standing in front of a graph.
Share Market News

Big ASX 200 news! Stock market whipsaws as Trump's tariffs struck down

Markets initially surged on news that Trump's tariffs are out.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Broker Notes

Guess which ASX 200 share Goldman Sachs just downgraded

The broker is calling time on this stock's rally.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »